Skip to main content
NUTRITION 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Session: Exemplary Trainee Abstracts in Obesity Science Research (Poster Theater Flash Session 4)

(PTFS04-02-23) Nanoencapsulated Resveratrol and Quercetin: Anti-Obesity Effects in Human Fecal Microbiota Transplant C57BL/6J Mice

Sunday, July 23, 2023
10:09 AM – 10:13 AM ET
Location:  Fairfax
ELPC

    Presenting Author(s)

  • Fang Zhou

    PhD student, RA
    Arizona State University
    Tempe, Arizona, United States

    Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.

    • Co-Author(s)

  • ZF

    Zhaoyang Fan

    Arizona State University

  • SW

    Shu Wang, MD, PhD

    Faculty
    Arizona State University
    Phoenix, Arizona, United States

Disclosure(s):
Fang Zhou: No relevant financial relationship(s) with ineligible companies to disclose.
Objectives: Obesity is a major public health issue. Many phytochemicals have anti-obesity properties, however, their low levels of solubility and bioavailability limit their application in obesity treatment. This is particular true for trans-resveratrol (R) and quercetin (Q). Encapsulating R and Q into lipid nanoparticles (NPs) can overcome these issues. In addition, the gut microbiota (GM) is linked to obesity. Thus, we aimed to investigate the anti-obesity effects of free R and Q (free-RQ), and R and Q encapsulated nanoparticles (RQ-NPs) in high-fat diet (HFD)-induced obese mice with and without healthy human fecal microbiota transplantation (FMT).

Methods: Male C57BL/6J mice (6-week-old) were randomized into one of the following 6 HFD groups: control, FMT, free-RQ, RQ-NPs, free-RQ + FMT, and RQ-NPs + FMT. FMT was given to antibiotic-treated mice weekly. R and Q were given to mice three times per week via oral gavage at 10 mg/kg body weight for 10 weeks. Body weight and body composition were measured weekly, and energy expenditure (EE), glucose tolerance test (GTT), plasma lipid profiles, liver functional enzymes and inflammatory markers were measured.

Results: RQ-NPs-treated mice with or without FMT had 17% and 21% lower body weight compared to the control mice, respectively. RQ-NPs-treated mice with or without FMT had 38% and 30% lower fat mass than the control mice, respectively. Increased EE was reflected by increased O2 consumption and CO2 release in RQ-NPs-treated mice with or without FMT. Compared to the control mice, RQ-NPs treatment with or without FMT showed 32% and 25% lower area under the curve during GTT. RQ-NPs-treated mice with or without FMT also had 90% and 80% increase in HDL levels, and 13% and 15% decrease in LDL/VLDL levels, respectively. RQ-NPs treatment with or without FMT decreased blood AST and ALT levels that were correlated with lowered expression of liver inflammatory factor genes. Results also indicated that RQ-NPs with or without FMT treatment showed better anti-obesity effects compared with free-RQ with or without FMT treatment in these measurements.

Conclusions: Oral administration of RQ-NPs decreased body weight and fat mass, improved glucose homeostasis, decreased liver inflammatory response and liver damage in HFD-fed obese mice, regardless of gut microbiota origin.

Funding Sources: Grant 19AIREA34480011 (AHA)